Please assess the completion status of the following clinical trial:

Trial Title: Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infected adults (\<17 y.o.)~2. Antiretroviral-naïve.~3. Be able to comply with protocol requirements and instructions.~4. Subject or the subject's representative capable of giving signed informed consent.~Exclusion Criteria:~1. Women who are breastfeeding or plan to become pregnant during the study.~2. Patients who in the investigator's judgment, poses a significant drop out risk or life expectancy inferior to study ending.~3. Patients with anticipated need to change the ART before study ending.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HIV-1 ART-Naive (Type: None): Lamivudine (300 mg p.o. q 24 h) plus Dolutegravir (50 mg p.o. q 24 h)

Based on this trial design, predict the completion outcome and termination type (if applicable).